Literature DB >> 15827176

An unrelated monoclonal antibody neutralizes human immunodeficiency virus type 1 by binding to an artificial epitope engineered in a functionally neutral region of the viral envelope glycoproteins.

Xinping Ren1, Joseph Sodroski, Xinzhen Yang.   

Abstract

Neutralizing antibodies often recognize regions of viral envelope glycoproteins that play a role in receptor binding or other aspects of virus entry. To address whether this is a necessary feature of a neutralizing antibody, we identified the V4 region of the gp120 envelope glycoprotein of human immunodeficiency virus type 1 (HIV-1) as a sequence that is tolerant of drastic change and thus appears to play a negligible role in envelope glycoprotein function. An artificial epitope tag was inserted into the V4 region without a significant effect on virus entry or neutralization by antibodies that recognize HIV-1 envelope glycoprotein sequences. An antibody directed against the artificial epitope tag was able to neutralize the modified, but not the wild-type, HIV-1. Thus, the specific target of a neutralizing antibody need not contribute functionally to the process of virus entry.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15827176      PMCID: PMC1082744          DOI: 10.1128/JVI.79.9.5616-5624.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  74 in total

1.  CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.

Authors:  A Trkola; T Dragic; J Arthos; J M Binley; W C Olson; G P Allaway; C Cheng-Mayer; J Robinson; P J Maddon; J P Moore
Journal:  Nature       Date:  1996-11-14       Impact factor: 49.962

2.  Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV type 1 isolate on viral envelope structure, cell entry, and replication.

Authors:  L Stamatatos; M Wiskerchen; C Cheng-Mayer
Journal:  AIDS Res Hum Retroviruses       Date:  1998-09-01       Impact factor: 2.205

3.  env gene sequences of primary HIV type 1 isolates of subtypes B, C, D, E, and F obtained from the World Health Organization Network for HIV Isolation and Characterization.

Authors:  M A Penny; S J Thomas; N W Douglas; S Ranjbar; H Holmes; R S Daniels
Journal:  AIDS Res Hum Retroviruses       Date:  1996-05-20       Impact factor: 2.205

4.  CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.

Authors:  L Wu; N P Gerard; R Wyatt; H Choe; C Parolin; N Ruffing; A Borsetti; A A Cardoso; E Desjardin; W Newman; C Gerard; J Sodroski
Journal:  Nature       Date:  1996-11-14       Impact factor: 49.962

5.  Stoichiometry of antibody neutralization of human immunodeficiency virus type 1.

Authors:  Xinzhen Yang; Svetla Kurteva; Sandra Lee; Joseph Sodroski
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

6.  The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry.

Authors:  C C Bleul; M Farzan; H Choe; C Parolin; I Clark-Lewis; J Sodroski; T A Springer
Journal:  Nature       Date:  1996-08-29       Impact factor: 49.962

7.  The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1.

Authors:  E Oberlin; A Amara; F Bachelerie; C Bessia; J L Virelizier; F Arenzana-Seisdedos; O Schwartz; J M Heard; I Clark-Lewis; D F Legler; M Loetscher; M Baggiolini; B Moser
Journal:  Nature       Date:  1996-08-29       Impact factor: 49.962

8.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.

Authors:  P D Kwong; R Wyatt; J Robinson; R W Sweet; J Sodroski; W A Hendrickson
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

9.  The antigenic structure of the HIV gp120 envelope glycoprotein.

Authors:  R Wyatt; P D Kwong; E Desjardins; R W Sweet; J Robinson; W A Hendrickson; J G Sodroski
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

10.  Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies.

Authors:  N Sullivan; Y Sun; J Binley; J Lee; C F Barbas; P W Parren; D R Burton; J Sodroski
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

View more
  26 in total

Review 1.  Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

Authors:  Barton F Haynes; David C Montefiori
Journal:  Expert Rev Vaccines       Date:  2006-06       Impact factor: 5.217

2.  Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeys.

Authors:  Wendy W Yeh; Laura M Brassard; Caroline A Miller; Aravind Basavapathruni; Jinrong Zhang; Srinivas S Rao; Gary J Nabel; John R Mascola; Norman L Letvin; Michael S Seaman
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

3.  Antibody binding in proximity to the receptor/glycoprotein complex leads to a basal level of virus neutralization.

Authors:  Xinzhen Yang; Inna Lipchina; Michelle Lifton; Liping Wang; Joseph Sodroski
Journal:  J Virol       Date:  2007-05-30       Impact factor: 5.103

4.  Infectivity and neutralization of simian immunodeficiency virus with FLAG epitope insertion in gp120 variable loops.

Authors:  Melissa E Laird; Ronald C Desrosiers
Journal:  J Virol       Date:  2007-08-08       Impact factor: 5.103

5.  Variable region 4 of SIV envelope correlates with rapid disease progression in morphine-exposed macaques infected with SIV/SHIV.

Authors:  Vanessa Rivera-Amill; Richard J Noel; Suheydi Orsini; Griselle Tirado; José M García; Shilpa Buch; Anil Kumar
Journal:  Virology       Date:  2006-09-28       Impact factor: 3.616

6.  Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection.

Authors:  Rui Kong; Hui Li; Frederic Bibollet-Ruche; Julie M Decker; Natalie N Zheng; Geoffrey S Gottlieb; Nancy B Kiviat; Papa Salif Sow; Ivelin Georgiev; Beatrice H Hahn; Peter D Kwong; James E Robinson; George M Shaw
Journal:  J Virol       Date:  2011-10-26       Impact factor: 5.103

7.  PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4.

Authors:  Emilia Falkowska; Alejandra Ramos; Yu Feng; Tongqing Zhou; Stephanie Moquin; Laura M Walker; Xueling Wu; Michael S Seaman; Terri Wrin; Peter D Kwong; Richard T Wyatt; John R Mascola; Pascal Poignard; Dennis R Burton
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

8.  The V4 and V5 Variable Loops of HIV-1 Envelope Glycoprotein Are Tolerant to Insertion of Green Fluorescent Protein and Are Useful Targets for Labeling.

Authors:  Shuhei Nakane; Aikichi Iwamoto; Zene Matsuda
Journal:  J Biol Chem       Date:  2015-04-24       Impact factor: 5.157

9.  Introduction of exogenous epitopes in the variable regions of the human immunodeficiency virus type 1 envelope glycoprotein: effect on viral infectivity and the neutralization phenotype.

Authors:  Aaron Wallace; Leonidas Stamatatos
Journal:  J Virol       Date:  2009-06-03       Impact factor: 5.103

10.  A strategy for eliciting antibodies against cryptic, conserved, conformationally dependent epitopes of HIV envelope glycoprotein.

Authors:  Hanna C Kelker; Vincenza R Itri; Fred T Valentine
Journal:  PLoS One       Date:  2010-01-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.